Mitochondrial Dna Copy Number As a Hidden Player in the Progression of Multiple Sclerosis: A Bidirectional Two-Sample Mendelian Randomization Study Publisher



Sabaie H¹ ; Taghavi Rad A¹ ; Shabestari M² ; Habibi D³ ; Saadattalab T⁴ ; Seddiq S⁵ ; Saeidian AH^{6, 7} ; Zahedi AS¹ ; Sanoie M¹ ; Vahidnezhad H^{6, 8, 9} ; Zarkesh M¹ ; Foroutani L¹⁰ ; Hakonarson H^{6, 8, 9, 11, 12} ; Azizi F¹³ Show All Authors Show Affiliations
Source: Molecular Neurobiology Published:2025

Abstract

The relationship between mitochondrial DNA copy number (mtDNA-CN) and multiple sclerosis (MS) progression remains unclear, as previous observational studies have reported conflicting results. This study aimed to clarify the association between mtDNA-CN and MS progression using a bidirectional two-sample Mendelian randomization (MR) approach. MR analyses were conducted using the latest summary statistics from genome-wide association studies (GWAS) on mtDNA-CN and MS progression. Single-nucleotide polymorphisms (SNPs) associated with mtDNA-CN were extracted from 383,476 participants of European ancestry in the UK Biobank, while SNPs associated with MS severity were obtained from the International Multiple Sclerosis Genetics Consortium (IMSGC), comprising 12,584 cases of European ancestry. The inverse variance weighted (IVW) method was used as the primary analysis. Potential heterogeneity and pleiotropy were evaluated, and sensitivity analyses were performed to ensure the robustness of the results. The forward MR analysis using the IVW method revealed no significant association between mtDNA-CN and MS progression (P = 0.487). However, reverse MR analysis identified a causal association between MS progression and mtDNA-CN (β = − 0.010, 95% CI = − 0.019 to − 0.001, P = 0.036). No evidence of heterogeneity or horizontal pleiotropy was found in the analyses. Sensitivity analyses yielded consistent results. Our findings suggest that MS progression may causally influence mtDNA-CN, highlighting the crucial role of mitochondria in the pathophysiology of MS. However, further research is needed to confirm mtDNA-CN as a reliable biomarker and a deeper understanding of the molecular mechanisms is necessary to develop targeted therapeutic interventions. © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2025.